Call for Abstract

5th International Conference on Antibiotics & Antibiotic Resistance , will be organized around the theme “The Antibiotic Resistance Crisis: Causes and Threats”

Antibiotics Resistance 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Antibiotics Resistance 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including  triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.  

 

Antibiotics are also noted as antibacterials, are types of medications that destroy or slow down the growth of bacteria. Alexander Fleming discovered first penicillin, the first chemical compound with antibiotic properties. Some of the common antibiotics are Aminoglycosides, Cephalosporins, Carbapenems, Macrolides, Penicillin, Quinolones, Sulfonamides and, Tetracyclines etc. General fundamentals of antibiotic prescribing are use: First-line antibiotics first, Reserve broad spectrum antibiotics for marked circumstances only, prescribe antibiotics for bacterial infections if Symptoms are significant or severe.

Antibiotics must be used accordingly in humans and animals because both uses share to the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food-producing animals are of particular concern. Food animals play as a source of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans through the foods we eat. Some bacteria have turned resistant to more than one sort of antibiotic, which makes it more difficult to treat the infections they cause. Sustaining the efficiency of antibiotic drugs is vital to insulating human and animal health.

Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumour products, antibiotics, immunosuppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamped such constraints that might further expand the promise of drugs from environmental microbes.

Prescribing doctors are, progressively, using clinical trial data as a major source of information for evidence-based medicine for the remedy of infectious diseases, as in other clinical disciplines. However, it may be difficult to excerpt from these data the material that is needed for the management of the individual patient. At the same time, clinical trial testimony have been used, probably satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent progressively large amount of money to satisfy the needs of this process. In the face of all these problems, switch in the way antibiotic clinical trials are designed and performed are clearly necessary, although this must not disturb the balance so far as to restore them less useful for those who currently derive greatest benefit from them.

The discovery of a new antibiotic called teixobactin was announced by international team of researchers, in January this year. It is the most significant new antibiotic to be discovered in more than 30 years, and it may help combat the growing number of drug-resistant bacteria.

This new method uses the enzymes of bacteriophages to attack the bacteria. Bacteriophages are tiny viruses that infect bacteria. After they infect the bacteria, they replicate or make copies of themselves, and then leave the bacteria to go and infect other bacteria. To be able to leave the bacteria, the "phages" make an enzyme that dissolves the wall of the bacterial cell, thus killing it.

  • Track 9-1Bacterial Spectrum
  • Track 9-2Route of Administration
  • Track 9-3Type of Activity
  • Track 9-4Based on Cidal or Static Action
  • Track 9-5Based on Mechanism of Action of the Drugs
  • Track 9-6Inhibition of bacterial cell wall synthesis
  • Track 9-7Impairment of cell membrane functions by increasing permeability
  • Track 9-8Interference with microtubules and microfilaments
  • Track 9-9Inhibition of protein synthesis
  • Track 9-10Inhibition of nucleic acid synthesis

Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

 

  • Track 11-1Genomic Analysis and Resistance Mechanisms
  • Track 11-2Evolutionary Trajectories to Antibiotic Resistance
  • Track 11-3Persistence of antibiotic resistance plasmids in bacterial biofilms
  • Track 11-4Development of botanicals to combat antibiotic resistance
  • Track 12-1Proteomics of Antimicrobial Resistance
  • Track 12-2Proteome studies of bacterial antibiotic resistance mechanisms
  • Track 12-3Insights from protein-protein interaction studies on bacterial pathogenesis
  • Track 13-1Molecular mechanism of resistance
  • Track 13-2A public approach to antimicrobial resistance
  • Track 13-3Bacterial antibiotic resistance
  • Track 13-4New drugs for emerging diseases
  • Track 13-5Alternate strategy to overcome the problem of antimicrobial resistance
  • Track 14-1Phytotherapy
  • Track 14-2Photodynamic inactivation
  • Track 14-3Photo-deposited silver coatings
  • Track 14-4Photodynamic Combination therapy
  • Track 14-5Functional Silver Nano composites
  • Track 14-6Engineered monolayer poration
  • Track 15-1Antimicrobial Resistance Epidemiology
  • Track 15-2Concerns on Pathogen Resistance
  • Track 15-3Unregulated use of antibiotics
  • Track 15-4Unnecessary prescribing of antibiotics
  • Track 15-5OTC availability of antibiotics
  • Track 15-6Non-compliance to drug regime
  • Track 15-7Stringent action on OTC antibiotics availability
  • Track 16-1Control over antibiotics prescriptions
  • Track 16-2Vigilance on use of drugs
  • Track 16-3Vigilance on herbal products and food supplements
  • Track 16-4Use of antibiotics during pregnancy
  • Track 16-5Use of antibiotics in paediatrics
  • Track 16-6Side effects of antibiotics
  • Track 17-1Bio analytical methods
  • Track 17-2Mass spectrometric strategies
  • Track 17-3Mass spectrometric strategies
  • Track 17-4Microbiological Analysis of Microbes
  • Track 17-5Resistance Gene Expression
  • Track 17-6Development of MAST: Microscopy based Antimicrobial Susceptibility Testing
  • Track 18-1Antibiotics chronic respiratory diseases
  • Track 18-2Antibiotics chronic inflammatory diseases
  • Track 18-3Antibiotics in cancer
  • Track 18-4Antibiotics in Diabetes
  • Track 18-5Antibiotics in Pregnancy